One‐week radiotherapy course shown to be safe and effective in the long term for early‐stage breast cancer
Groundbreaking research from the FAST-Forward trial, spearheaded by Keele University oncologist Professor Murray Brunt and sponsored by The Institute of Cancer Research, London, has conclusively shown that a one-week course of post-surgical radiotherapy is as safe and effective as the traditional three-week regimen for individuals with early-stage breast cancer. This pivotal decade-long study, meticulously tracking over 4,000 patients, marks a significant paradigm shift in oncology, validating a condensed treatment schedule and offering a new standard for adjuvant therapy.















